Blue Biotechnology Market

Increasing Awareness of Blue Biotechnology-Based Nutraceuticals and Pharmaceuticals

The increasing awareness of blue biotechnology-based nutraceuticals and pharmaceuticals is playing a pivotal role in fueling the growth of the blue biotechnology market. As consumers become more conscious of the health benefits offered by marine-derived compounds, there is a growing demand for products derived from marine organisms.

Nutraceuticals containing marine ingredients such as omega-3 fatty acids, antioxidants, and minerals are gaining popularity due to their perceived health-promoting properties. For instance, Cyanotech Corporation (US) manufactures BioAstin Hawaiian Astaxanthin, which is a nutrient powder that treats immune, skin, and joint health.

Moreover, pharmaceuticals developed from marine organisms are garnering attention for their potential in treating various diseases, including cancer, infectious diseases, and neurological disorders. For instance, PharmaMar (Spain) manufacturer Yondelis compound derived from the colonial sea squirt ecteinascidia turbinata recommends treating soft tissue sarcoma as a monotherapy.

Furthermore, it is also utilized in treating ovarian cancer in combination with Doxil (PLD). Moreover, Eisai Co., Ltd. (Japan) manufactures HALAVEN injection, which is developed from a natural substance found in a sea sponge and is utilized to treat unresectable or metastatic liposarcoma.

Strategic acquisition and product launch in marine biotechnology are accelerating the discovery, development, and commercialization of novel marine-derived compounds. These initiatives not only broaden the product pipeline, but also promote technological advancements in fields such as bioprospecting, bioprocessing, and marine genomics.

For instance, in July 2019, Aker BioMarine (Norway) acquired Lang Pharma Nutrition (US) which has 35 years of history in the nutrition & dietary supplement and focus on health-benefit driven products. Lang will aid Aker BioMarine expand its brand in the US.

Thus, the Blue Biotechnology Market is expanding due to rising awareness of blue biotechnology-based nutraceuticals and pharmaceuticals, as well as strategic initiatives focused on marine organisms.

The Global Blue Biotechnology Market Industry is projected to experience substantial growth in the coming years. With an expected market size of 5.65 USD Billion in 2024, the industry is set to expand significantly, reaching 13.0 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate (CAGR) of 7.84% from 2025 to 2035, indicating a robust interest in marine biotechnology. The increasing recognition of the potential of marine resources in various applications, including pharmaceuticals and environmental sustainability, is likely to drive this growth.

Government initiatives and funding play a crucial role in the growth of the Global Blue Biotechnology Market Industry. Various countries are recognizing the economic potential of marine resources and are investing in research and development to promote innovation in this field. For example, funding programs aimed at supporting marine research projects are becoming increasingly common. This support not only fosters innovation but also encourages collaboration between academia and industry. As a result, the market is likely to experience a compound annual growth rate (CAGR) of 7.84% from 2025 to 2035, driven by enhanced research capabilities and technological advancements.

The Global Blue Biotechnology Market Industry is experiencing a surge in emerging applications within the healthcare sector. Marine organisms are being explored for their therapeutic potential, particularly in drug discovery and development. Compounds derived from marine sources have shown promise in treating various diseases, including cancer and inflammatory disorders. This trend is expected to contribute to the market's expansion, with projections indicating a growth to 13.0 USD Billion by 2035. The increasing focus on marine-derived pharmaceuticals reflects a broader shift towards utilizing natural resources for innovative healthcare solutions.

Technological advancements in marine biotechnology are propelling the Global Blue Biotechnology Market Industry forward. Innovations in genetic engineering and bioinformatics are enabling researchers to harness the genetic diversity of marine organisms, leading to the discovery of novel bioactive compounds. These compounds have applications in pharmaceuticals, nutraceuticals, and cosmetics. The market is expected to grow significantly, with projections indicating a rise to 13.0 USD Billion by 2035. This growth is indicative of the potential that marine resources hold in contributing to health and wellness, thereby attracting investments and research initiatives.

There is a growing awareness of the importance of marine ecosystems and their potential contributions to biotechnology. The Global Blue Biotechnology Market Industry is benefiting from increased public interest in marine conservation and the sustainable use of ocean resources. Educational campaigns and initiatives aimed at promoting the value of marine biodiversity are fostering a culture of sustainability. This heightened awareness is likely to drive demand for marine-derived products, as consumers become more conscious of their choices. As the market continues to evolve, it is anticipated that the integration of sustainable practices will further enhance its growth trajectory.

The Global Blue Biotechnology Market Industry is witnessing an increasing demand for sustainable solutions across various sectors, including pharmaceuticals, agriculture, and food production. This shift is largely driven by the need to reduce environmental impact and promote sustainable practices. For instance, marine-derived compounds are being explored for their potential in drug development, which aligns with the global push towards sustainability. As the market evolves, it is projected to reach 5.65 USD Billion in 2024, reflecting a growing recognition of the importance of blue biotechnology in addressing ecological challenges.

By region, the market is divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the largest market share of over 36.04% in 2023, owing to the increasing investment in research and development activities, advanced healthcare infrastructure, and presence of established drug manufacturers in North America.

Further, the presence of renowned market players who are actively involved in fulfilling consumer demand in the region is burgeoning the region’s market growth. For instance, Cyanotech Corporation (US) sells BioAstin through Nutrex Hawaii as a packaged consumer product to natural product distributors, retailers, and online channels, as well as directly to consumers.

It is also supplied as a raw ingredient to dietary supplements, health foods, and cosmetic manufacturers in the form of liquid lipids. BioAstin gelcaps are available in bulk to international distributors. Thus, the presence of such market players, who are expanding their presence through distributors and online channels, is fostering the region’s growth.

Further, the major countries studied are: The US, Canada, Brazil, Germany, France, the UK, Italy, Spain, China, India, Japan, South Korea, and Australia.

FIGURE 3: BLUE BIOTECHNOLOGY MARKET, BY REGION, 2023 & 2032 (USD BILLION)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

The Europe blue biotechnology market shows significant growth during the forecast year, i.e., 2024–2032, owing to the presence of huge start-ups associated with blue biotechnology. For instance, Calouste Gulbenkian and the Oceano Azul Foundations, both headquartered in Portugal, received more than 120 projects from over 30 countries until September 2020 associated with blue biotechnology.

Further, in September 2020, Blue Bio Value (Portugal) launched its acceleration program for startups related to the blue bioeconomy with 15 projects from eight different countries in Europe: Portugal, Spain, France, Ireland, Italy, The Netherlands, and the United Kingdom. The Germany blue biotechnology market held the largest market share in 2023, and the UK blue biotechnology market is the fastest-growing market in the Europe region.

The Asia-Pacific blue biotechnology market is the fastest-growing region during the forecast period owing to high demand for marine-derived products in various industries including agriculture, pharmaceuticals, cosmetics, among others. Furthermore, advances in biotechnological tools and techniques, such as genomics, proteomics, and metabolomics, have made it easier to investigate and exploit marine resources which is burgeoning the market growth.

These technologies allow researchers to more efficiently identify, isolate, and produce valuable compounds from marine organisms. Moreover, China blue biotechnology market held the largest market share in 2023 and India blue biotechnology market is the fastest growing market in the Asia-Pacific region.

The blue biotechnology market is distinguished by the presence of many global, regional, and local players. The increasing awareness of blue biotechnology-based nutraceuticals and pharmaceuticals and strategic initiatives associated with pharmaceuticals and nutraceuticals sourced from marine organisms are further expected to drive the growth of the blue biotechnology market during the forecast period.

However, stringent regulatory policies may hamper the growth of the blue biotechnology market. The major players have adopted a strategy of obtaining regulatory approval from government agencies for their devices and signing contracts and agreements to broaden their reach and reduce operational costs.

Marinomed Biotech AG (Austria) is a growing Austrian biopharmaceutical company with a focus on innovative therapies for respiratory and immunological diseases.Marinomed specializes in creating cutting-edge treatments for conditions related to virology and immunology.

Leveraging the virus-blocking capabilities of Carragelose, the company has introduced a range of over-the-counter products designed to combat viral respiratory infections. Recently, the company further diversified its portfolio by introducing an allergen-blocking nasal spray and hydrating eye drops in the field of immunology.

Moreover, in March 2024, the company entered into partnerships with GAIA Healthcare FZ LLC (UAE) and VitaPlus Kft (Hungary) for the distribution of Carragelose nasal sprays distribution for Gulf region and Eastern Europe